MMPs in the central nervous system: where the good guys go bad.

Matrix metalloproteinases (MMPs) are expressed in the developing, healthy adult and diseased CNS. We emphasize the regulation of neurogenesis and oligodendrogenesis by MMPs during CNS development, and highlight physiological roles of MMPs in the healthy adult CNS, such as in synaptic plasticity, learning and memory. Nonetheless, MMPs as "the good guys" go bad in neurological conditions, likely aided by the sudden and massive upregulation of several MMP members. We stress the necessity of drawing a fine balance in the treatment of neurological diseases, and we suggest that MMP inhibitors do have therapeutic potential early after CNS injury.

[1]  F. Scaravilli,et al.  The Changing Pattern of HIV Neuropathology in the HAART Era , 2003, Journal of neuropathology and experimental neurology.

[2]  L. Lund,et al.  MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum , 2003, Molecular and Cellular Neuroscience.

[3]  R. Muschel,et al.  Developmental expression of MMP‐9 (gelatinase B) mRNA in mouse embryos , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[4]  Z. Werb,et al.  Involvement of tissue inhibition of metalloproteinases-1 in learning and memory in mice , 2006, Behavioural Brain Research.

[5]  D. Jaworski,et al.  Regulation of tissue inhibitor of metalloproteinase‐3 (Timp‐3) mRNA expression during rat CNS development , 2000, Journal of neuroscience research.

[6]  M. Schwartz.  Macrophages and Microglia in Central Nervous System Injury: Are They Helpful or Harmful? , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  E. Masliah,et al.  Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis , 2002, Neurology.

[8]  F. Chiodi,et al.  Human immunodeficiency virus infection of the brain II. Detection of intrathecally synthesized antibodies by enzyme linked immunosorbent assay and imprint immunofixation , 1988, Journal of the Neurological Sciences.

[9]  David A Ramsay,et al.  The cellular inflammatory response in human spinal cords after injury. , 2006, Brain : a journal of neurology.

[10]  A. Stalder,et al.  Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. , 1998, The American journal of pathology.

[11]  A. Shinagawa,et al.  Expression of the membrane-type 3 matrix metalloproteinase (MT3-MMP) in human brain tissues , 1998, Acta Neuropathologica.

[12]  Dr. med. Hans Lassmann.  Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis , 1983, Schriftenreihe Neurologie / Neurology Series.

[13]  L. Noble,et al.  Matrix Metalloproteinases Limit Functional Recovery after Spinal Cord Injury by Modulation of Early Vascular Events , 2002, The Journal of Neuroscience.

[14]  F. Sellebjerg,et al.  Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system , 2003, Brain Research Bulletin.

[15]  J. Newcombe,et al.  The Expression of Tissue‐type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis: Comparison of Stages in Lesion Evolution , 1996, Journal of neuropathology and experimental neurology.

[16]  J. Berman,et al.  CCL2/Monocyte Chemoattractant Protein-1 Mediates Enhanced Transmigration of Human Immunodeficiency Virus (HIV)-Infected Leukocytes across the Blood–Brain Barrier: A Potential Mechanism of HIV–CNS Invasion and NeuroAIDS , 2006, The Journal of Neuroscience.

[17]  R. Dwek,et al.  Remnant epitopes, autoimmunity and glycosylation. , 2006, Biochimica et Biophysica Acta.

[18]  G. Opdenakker,et al.  Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis , 2006, The Journal of experimental medicine.

[19]  M. Duddy,et al.  Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. , 2003, Brain : a journal of neurology.

[20]  R. Buist,et al.  Metalloproteinases Control Brain Inflammation Induced by Pertussis Toxin in Mice Overexpressing the Chemokine CCL2 in the Central Nervous System1 , 2006, The Journal of Immunology.

[21]  J. Dequeker,et al.  Gelatinase B in chronic synovitis: immunolocalization with a monoclonal antibody. , 1997, British journal of rheumatology.

[22]  P. Popovich,et al.  Rats and mice exhibit distinct inflammatory reactions after spinal cord injury , 2003, The Journal of comparative neurology.

[23]  J. Hocking,et al.  Matrix metalloproteinases are required for retinal ganglion cell axon guidance at select decision points , 2005, Development.

[24]  K. Conant,et al.  Transplanted neural stem cells promote axonal regeneration through chronically denervated peripheral nerves , 2004, Experimental Neurology.

[25]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[26]  D. Edwards,et al.  Key Metalloproteinases Are Expressed by Specific Cell Types in Experimental Autoimmune Encephalomyelitis1 , 2004, The Journal of Immunology.

[27]  M. Louder,et al.  Overexpression of nef as a marker for restricted HIV‐1 infection of astrocytes in postmortem pediatric central nervous tissues , 1994, Neurology.

[28]  Manuel Buttini,et al.  An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. , 1997, Journal of neurovirology.

[29]  M. D. Del Bigio,et al.  Localization of proteinase expression in the developing rabbit brain. , 1995, Brain research. Developmental brain research.

[30]  V. Yong,et al.  Metalloproteinases: Mediators of Pathology and Regeneration in the CNS , 2005, Nature Reviews Neuroscience.

[31]  E. Lo,et al.  Involvement of Matrix Metalloproteinase in Neuroblast Cell Migration from the Subventricular Zone after Stroke , 2006, The Journal of Neuroscience.

[32]  G. Opdenakker,et al.  Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis , 2003, The Lancet Neurology.

[33]  P Bacchetti,et al.  Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. , 1999, Neurology.

[34]  G. Nuovo,et al.  AIDS Dementia Is Associated with Massive, Activated HIV-1 Infection and Concomitant Expression of Several Cytokines , 1996, Molecular medicine.

[35]  L. Kappos,et al.  Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. , 1998, Brain : a journal of neurology.

[36]  V. Yong,et al.  Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators , 2007, Journal of the Neurological Sciences.

[37]  G. Schultz,et al.  Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene. , 2002, The Biochemical journal.

[38]  G. Opdenakker,et al.  A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys αB-crystallin and generates a promiscuous T cell epitope , 2003, Journal of Neuroimmunology.

[39]  E. Masliah,et al.  Cortical Synaptic Density is Reduced in Mild to Moderate Human Immunodeficiency Virus Neurocognitive Disorder , 1999, Brain pathology.

[40]  M. Trojano,et al.  Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes , 2003, Journal of Neuroimmunology.

[41]  Jia Luo.  The role of matrix metalloproteinases in the morphogenesis of the cerebellar cortex , 2008, The Cerebellum.

[42]  S. Kushimoto,et al.  Role of neutrophils in spinal cord injury in the rat , 1997, Neuroscience.

[43]  E. Ziff,et al.  Membrane Localization of Membrane Type 5 Matrix Metalloproteinase by AMPA Receptor Binding Protein and Cleavage of Cadherins , 2006, The Journal of Neuroscience.

[44]  B. Brew,et al.  Expression of chemokines and their receptors in human and simian astrocytes: Evidence for a central role of TNFα and IFNγ in CXCR4 and CCR5 modulation , 2003 .

[45]  J. Seoh,et al.  Increased activity of matrix metalloproteinase-2 in human glial and neuronal cell lines treated with HIV-1 gp41 peptides , 1998, Journal of Molecular Neuroscience.

[46]  V. Kuchroo,et al.  Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation , 2007, Nature Medicine.

[47]  M. Trojano,et al.  Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis , 2002, Multiple sclerosis.

[48]  G. Opdenakker,et al.  Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. , 1993, Biochemical and biophysical research communications.

[49]  J. Wallace,et al.  Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. , 2002, Blood.

[50]  S. Zamvil,et al.  T effectors outfox T regulators in autoimmunity , 2007, Nature Medicine.

[51]  P. E. Van den Steen,et al.  Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.

[52]  G. Opdenakker,et al.  Matrix Metalloproteinase-9 Facilitates Remyelination in Part by Processing the Inhibitory NG2 Proteoglycan , 2003, The Journal of Neuroscience.

[53]  J. Albert,et al.  Human immunodeficiency virus infection of the brain I. Virus isolation and detection of HIV specific antibodies in the cerebrospinal fluid of patients with varying clinical conditions , 1988, Journal of the Neurological Sciences.

[54]  Hiroyuki Arai,et al.  Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain‐specific MMP highly expressed in cerebellum , 2001, The European journal of neuroscience.

[55]  G. Opdenakker,et al.  In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[56]  D. Basso,et al.  The Neuropathological and Behavioral Consequences of Intraspinal Microglial/Macrophage Activation , 2002, Journal of neuropathology and experimental neurology.

[57]  W. Baumgärtner,et al.  Matrix Metalloproteinases and Their Inhibitors in the Developing Mouse Brain and Spinal Cord: A Reverse Transcription Quantitative Polymerase Chain Reaction Study , 2005, Developmental Neuroscience.

[58]  D. McAdoo,et al.  Metalloproteinase increases in the injured rat spinal cord , 2000, Neuroreport.

[59]  V. Wee Yong,et al.  An Adverse Role for Matrix Metalloproteinase 12 after Spinal Cord Injury in Mice , 2003, The Journal of Neuroscience.

[60]  S. Chandler,et al.  Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. , 1996, Biochemical and biophysical research communications.

[61]  M. Didier-Bazès,et al.  Spatiotemporal Expression Patterns of Metalloproteinases and Their Inhibitors in the Postnatal Developing Rat Cerebellum , 1999, The Journal of Neuroscience.

[62]  J. Leonard,et al.  Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790 , 1995, Inflammation Research.

[63]  R. Sciot,et al.  Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. , 1999, The Journal of clinical investigation.

[64]  A. Cuello,et al.  Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[65]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[66]  Barbara L. Hempstead,et al.  Regulation of Cell Survival by Secreted Proneurotrophins , 2001, Science.

[67]  O. Bozdagi,et al.  In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. , 2007, Journal of neurophysiology.

[68]  J. Cossins,et al.  Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor , 1997, Journal of Neuroimmunology.

[69]  R. Schulz,et al.  The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver. , 2006, Current pharmaceutical design.

[70]  Mikel L. Olson,et al.  Effects of extracellular matrix‐degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity , 2006, Journal of neurochemistry.

[71]  S. Mahooti,et al.  Distinct roles for matrix metalloproteinase-2 and α4 integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[72]  Sonia L. Carlson,et al.  Acute Inflammatory Response in Spinal Cord Following Impact Injury , 1998, Experimental Neurology.

[73]  Y. Persidsky,et al.  Immune privilege and HIV‐1 persistence in the CNS , 2006, Immunological reviews.

[74]  Z. Werb,et al.  Matrix Metalloproteinase-2 Facilitates Wound Healing Events That Promote Functional Recovery after Spinal Cord Injury , 2006, The Journal of Neuroscience.

[75]  R. M. Costanzo,et al.  Matrix metalloproteinase expression in the olfactory epithelium , 2003, Neuroreport.

[76]  B. Rosen,et al.  Role of matrix metalloproteinases in delayed cortical responses after stroke , 2006, Nature Medicine.

[77]  J. Cossins,et al.  Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions , 1997, Acta Neuropathologica.

[78]  Z. Ahmed,et al.  Matrix metalloproteases: degradation of the inhibitory environment of the transected optic nerve and the scar by regenerating axons , 2005, Molecular and Cellular Neuroscience.

[79]  H. D. de Vries,et al.  Matrix metalloproteinase‐19 is highly expressed in active multiple sclerosis lesions , 2006, Neuropathology and applied neurobiology.

[80]  G. Opdenakker,et al.  Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein , 1993, Journal of neuroscience research.

[81]  R. Muschel,et al.  MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. , 1995, Brain research. Developmental brain research.

[82]  E. Masliah,et al.  Dendritic injury is a pathological substrate for human immunodeficiency virus—related cognitive disorders , 1997, Annals of neurology.

[83]  R. Price,et al.  Infection of the Central Nervous System by Human Immunodeficiency Virus Role of the Immune System in Pathogenesis a , 1988, Annals of the New York Academy of Sciences.

[84]  V. Vullo,et al.  Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. , 2000, Journal of neurovirology.

[85]  J. Weiss,et al.  HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. , 1999, Journal of immunology.

[86]  Y. Itoh,et al.  Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[87]  Alcino J. Silva,et al.  Matrix Metalloproteinase-9 Is Required for Hippocampal Late-Phase Long-Term Potentiation and Memory , 2006, The Journal of Neuroscience.

[88]  P. Soloway,et al.  Tissue inhibitor of metalloproteinase-2(TIMP-2)-deficient mice display motor deficits. , 2006, Journal of neurobiology.

[89]  B. Fingleton,et al.  Matrix metalloproteinases as valid clinical targets. , 2007, Current pharmaceutical design.

[90]  J. Ward,et al.  MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover , 1999, Cell.

[91]  V. Yong,et al.  Characterization of the Early Neuroinflammation After Spinal Cord Injury in Mice , 2007, Journal of neuropathology and experimental neurology.

[92]  A. H. Drummond,et al.  Processing of tumour necrosis factor-α precursor by metalloproteinases , 1994, Nature.

[93]  L. Kaczmarek,et al.  Matrix Metalloproteinase-9 Undergoes Expression and Activation during Dendritic Remodeling in Adult Hippocampus , 2002, The Journal of Neuroscience.

[94]  J. Madri,et al.  MMP‐2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP‐9 expression and activity , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[95]  O. Stettler,et al.  MMP-Related Gelatinase Activity Is Strongly Induced in Scar Tissue of Injured Adult Spinal Cord and Forms Pathways for Ingrowing Neurites , 2001, Molecular and Cellular Neuroscience.

[96]  J. Palace,et al.  Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. , 1999, Brain : a journal of neurology.

[97]  Z. Werb,et al.  Matrix Metalloproteinase-9/Gelatinase B Is Required for Process Outgrowth by Oligodendrocytes , 1999, The Journal of Neuroscience.

[98]  E. Granieri,et al.  Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis , 2006, Multiple sclerosis.

[99]  P. Lantos,et al.  Neuronal pattern correlates with the severity of human immunodeficiency virus-associated dementia complex. Usefulness of spatial pattern analysis in clinicopathological studies. , 1996, The American journal of pathology.

[100]  K. Conant,et al.  Myelin Formation during Development of the CNS Is Delayed in Matrix Metalloproteinase-9 and -12 Null Mice , 2006, The Journal of Neuroscience.

[101]  E. Lo,et al.  Role of Matrix Metalloproteinases in Delayed Neuronal Damage after Transient Global Cerebral Ischemia , 2004, The Journal of Neuroscience.

[102]  E. Reinke,et al.  Dendritic Cell Transmigration through Brain Microvessel Endothelium Is Regulated by MIP-1α Chemokine and Matrix Metalloproteinases1 , 2007, The Journal of Immunology.

[103]  C. Justicia,et al.  Expression and Activation of Matrix Metalloproteinase-2 and -9 in Rat Brain after Transient Focal Cerebral Ischemia , 2001, Neurobiology of Disease.

[104]  J. Correale,et al.  Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS , 2003, Journal of Neuroimmunology.

[105]  W. Wachsman,et al.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection , 1992, Neurology.

[106]  Inge Nelissen,et al.  Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes. , 2003, Advances in experimental medicine and biology.

[107]  V. Perry,et al.  Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke , 1997, Neuropathology and applied neurobiology.

[108]  B. Stokes,et al.  Cellular inflammatory response after spinal cord injury in sprague‐dawley and lewis rats , 1997, The Journal of comparative neurology.

[109]  S. Shapiro,et al.  An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[110]  D. Ethell,et al.  Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets , 2007, Journal of neuroscience research.

[111]  A. Shinagawa,et al.  White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues , 2004, Acta Neuropathologica.

[112]  V. Vullo,et al.  Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients , 2007, AIDS.

[113]  R. Sobel,et al.  Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions , 1996, Journal of neuropathology and experimental neurology.

[114]  Takayuki Itoh,et al.  Microglia Express CCR5, CXCR4, and CCR3, but of These, CCR5 Is the Principal Coreceptor for Human Immunodeficiency Virus Type 1 Dementia Isolates , 1999, Journal of Virology.

[115]  A. Rudensky,et al.  Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3 , 2007, Nature Immunology.

[116]  S. Rivera,et al.  Matrix metalloproteinase‐2 (MMP‐2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins , 2006, Glia.